Alexander M. Gold
Alexander M. Gold
Alexander M. Gold, M.D., F.A.C.C. joined Sanifit in November 2017 as our Chief Medical Officer and President of the company’s U.S. subsidiary. Dr. Gold is a cardiologist and executive with expertise in development of new therapeutics and extensive experience in pharmaceutical and biotech industry.
Prior to joining Sanifit Dr. Gold was SVP and Head of Clinical Development at Portola Pharmaceuticals, where he built and led the clinical and medical affairs organization and was the clinical leader responsible for the NDA/MAA submission approved by FDA as BevyxXa in June of 2017; and the BLA/MAA submission for AndeXa (andexanet alpha). Prior to Portola Dr. Gold was Head of Clinical Development at Reata Pharmaceuticals after 11 years at AstraZeneca, where his last position was as Executive Director and Development Brand Leader for CRESTOR® and BRILINTA®. In these roles, he led teams and activities related to approval and commercialization of these products. During his career, he held multiple leadership positions in various therapeutic areas, including hematology, thrombosis, cardiometabolic, renal, inflammation, and oncology.
Dr. Gold is an Adjunct Professor at Stanford University School of Medicine and previously was a visiting lecturer at Penn Institute for Translational Medicine and Therapeutics (ITMAT). Dr. Gold has numerous publications in peer-reviewed journals, including New England Journal of Medicine, Circulation, and American Heart Journal. He presented and led symposia on diverse topics related to the science and development of innovative medicines.
Prior to joining industry Dr. Gold trained at Harvard Medical School and affiliated hospitals in internal medicine, cardiology and clinical research. He also received executive training at Wharton.